{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:30:52Z","timestamp":1772605852144,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.canrad.2025.104709","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:58:17Z","timestamp":1755741497000},"page":"104709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic radiotherapy for prostate cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Ulrike","family":"Schick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Josset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lacornerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyne","family":"Mazurier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10196","key":"10.1016\/j.canrad.2025.104709_bib0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.canrad.2025.104709_bib0120","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.canrad.2025.104709_bib0125","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.canrad.2025.104709_bib0130","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(25)00205-0","article-title":"Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial","volume":"26","author":"Tree","year":"2025","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104709_bib0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104709_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.01.014","article-title":"Dosimetric comparison of CyberKnife and conventional linac prostate stereotactic body radiation therapy plans: analysis of the PACE-B study","author":"Ratnakumaran","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104709_bib0145","first-page":"100907","article-title":"Urethra-sparing prostate cancer radiotherapy: current practices and future insights from an international survey","volume":"51","author":"Guevelou","year":"2025","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.canrad.2025.104709_bib0150","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"issue":"Suppl1","key":"10.1016\/j.canrad.2025.104709_bib0155","doi-asserted-by":"crossref","first-page":"S2009","DOI":"10.1016\/S0167-8140(25)01262-9","article-title":"2750 Exploring predictive factors for late urinary toxicity after prostate SBRT: findings from the PACE-B study","volume":"206","author":"Ratnakumaran","year":"2025","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104709_bib0160","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mp.16878","article-title":"Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): substructure with fraction-wise analysis","volume":"51","author":"Pham","year":"2024","journal-title":"Med Phys"},{"issue":"4","key":"10.1016\/j.canrad.2025.104709_bib0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2023.12.037","article-title":"Urethra-sparing prostate cancer stereotactic body radiation therapy: sexual function and radiation dose to the penile bulb, the crura, and the internal pudendal arteries from a randomized phase 2 trial","volume":"119","author":"Achard","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104709_bib0170","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2020.01.022","article-title":"Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultrahypofractionated and conventionally fractionated radiation therapy for prostate cancer","volume":"107","author":"Rasmusson","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"49","key":"10.1016\/j.canrad.2025.104709_bib0175","doi-asserted-by":"crossref","first-page":"e28111","DOI":"10.1097\/MD.0000000000028111","article-title":"SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: a systematic review","volume":"100","author":"Payne","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.canrad.2025.104709_bib0180","doi-asserted-by":"crossref","first-page":"110568","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104709_bib0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase 2 trial","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.canrad.2025.104709_bib0190","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.adro.2020.09.022","article-title":"Urinary outcomes for men with high baseline international prostate symptom scores treated with prostate SBRT","volume":"6","author":"Gorovets","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104709_bib0195","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3389\/fonc.2020.01060","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with a high baseline International Prostate Symptom Score (IPSS\u00a0\u2265\u00a015)","volume":"10","author":"Aghdam","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.canrad.2025.104709_bib0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.prro.2023.11.008","article-title":"Stereotactic body radiation therapy for the curative treatment of prostate cancer in ultralarge (\u2265\u00a0100\u00a0cm3) glands","volume":"14","author":"Hurwitz","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104709_bib0205","first-page":"100779","article-title":"Extreme hypofractionated stereotactic radiotherapy for localized prostate cancer: efficacy and late urinary toxicity according to transurethral resection of the prostate history","volume":"46","author":"Galienne","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.canrad.2025.104709_bib0210","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104709_bib0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"issue":"9","key":"10.1016\/j.canrad.2025.104709_bib0220","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1016\/j.clon.2022.05.021","article-title":"Surgical treatments of benign prostatic hyperplasia and prostate cancer stereotactic radiotherapy: impact on long-term genitourinary toxicity","volume":"34","author":"Huck","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:41:56Z","timestamp":1756932116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1278321825001258"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104709","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiotherapy for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104709"}}